
NASDAQHealthcareBiotechnology
Latest quote
$2.96
−$0.40 · -11.90%
ARS Pharmaceuticals, Inc. specializes in creating ARS-1, an innovative intranasal epinephrine spray utilizing advanced absorption technology. This product serves as a crucial intervention for individuals and their households who are susceptible to life-threatening allergic reactions caused by food, pharmaceuticals, or insect stings. Among its offerings is Neffy, a low-dose version of its intranasal epinephrine nasal spray. Established in 2015, the firm operates out of San Diego, California.
Previous close
$2.96
−$0.40 · -11.90%
Regular session · ET · Market data may be delayed.
ARS Pharmaceuticals, Inc. specializes in creating ARS-1, an innovative intranasal epinephrine spray utilizing advanced absorption technology. This product serves as a crucial intervention for individuals and their households who are susceptible to life-threatening allergic reactions caused by food, pharmaceuticals, or insect stings. Among its offerings is Neffy, a low-dose version of its intranasal epinephrine nasal spray. Established in 2015, the firm operates out of San Diego, California.
Day range
Current $2.96
52-week range
Current $2.96
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
42
Fair Value
Sentiment
36
Bearish
Risk
64
High Risk
Momentum
30
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
ARS Pharmaceuticals, Inc. specializes in creating ARS-1, an innovative intranasal epinephrine spray utilizing advanced absorption technology. This product serves as a crucial intervention for individuals and their households who are susceptible to life-threatening allergic reactions caused by food, pharmaceuticals, or insect stings. Among its offerings is Neffy, a low-dose version of its intranasal epinephrine nasal spray. Established in 2015, the firm operates out of San Diego, California.
Day range
Current $2.96
52-week range
Current $2.96
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 84.28M USD | 89.15M USD | 30K USD | 1.32M USD | 5.51M USD |
| Cost of goods sold | 20.42M USD | 20.56M USD | — | 17.12M USD | 213K USD |
| Gross profit | 63.86M USD | 68.59M USD | 30K USD | −15.8M USD | 5.29M USD |
| Research and development | 13.18M USD | 19.58M USD | 20.27M USD | 18.38M USD | 20.27M USD |
| Selling, general, and administrative | 230.12M USD | — | 47.28M USD | 18.66M USD | 4.69M USD |
| Operating expenses | 243.3M USD | 71.68M USD | 67.55M USD | 19.71M USD | 24.75M USD |
| Interest income | 10.67M USD | — | — | — | 800K USD |
| Interest expense | 2.6M USD | — | — | — | 106K USD |
| Depreciation and amortization | 1.37M USD | 79K USD | 73K USD | 319K USD | 213K USD |
| Operating income | −179.45M USD | −3.08M USD | −67.52M USD | −35.52M USD | −19.45M USD |
| Net income | −171.3M USD | 8M USD | −54.37M USD | −34.68M USD | −20.24M USD |
Company facts updated Nov 22, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Funds reporting this stock among their holdings, ordered by reported position size.
State Street SPDR S&P Biotech ETFXBI7.49M0.08%9.64B USD0.35%$140.18-2.73%
iShares Russell 2000 ETFIWM4.9M0.01%71.54B USD0.19%$256.61-2.88%
Vanguard Morningstar Total Stock Market ETFVTI4.66M0.00%689.3B USD0.03%$340.02-3.52%
Vanguard Extended Market ETFVXF2.35M0.00%30.2B USD0.05%$211.44-3.21%
iShares Russell 2000 Growth ETFIWO1.97M0.01%12.73B USD0.24%$320.43-3.57%
iShares Biotechnology ETFIBB1.44M0.01%10.53B USD0.44%$199.54-2.05%
Vanguard Russell 2000 ETFVTWO1.23M0.01%16.8B USD0.06%$103.76-2.76%
Schwab U.S. Small-Cap ETFSCHA1.11M0.01%20.45B USD0.03%$30.51-2.83%
State Street SPDR S&P Biotech ETFXBI
iShares Russell 2000 ETFIWM
Vanguard Morningstar Total Stock Market ETFVTI
Vanguard Extended Market ETFVXF
iShares Russell 2000 Growth ETFIWO
iShares Biotechnology ETFIBB
Vanguard Russell 2000 ETFVTWO
Schwab U.S. Small-Cap ETFSCHAAI-generated and delayed market data for informational and educational purposes only. Not investment advice.